Product Information

LITHIUM CARBONATE ER 300 MG TB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1959 per EA under NDC 64980020505. Its NADAC has been published 533 times since Jun 8, 2016.

FDA first approved this application on Jul 27, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

LITHIUM CARBONATE ER 300 MG TB

Lithium Carbonate
$0.1959per EA

Strength

300 mg/1

NDC

64980020505

Classification

Generic

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

LITHIUM CARBONATE

Approval Type

Generic (ANDA)

FDA Application

ANDA204779

FDA Approved

7/27/2015

TE Code

AB

On Market Since

3/23/2016

Pharmacological Classes

Price Statistics

The NADAC for LITHIUM CARBONATE ER 300 MG TB has been published 533 times since Jun 8, 2016, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$0.1959 per EA
All-time high$0.2271 (Nov 13, 2024)
All-time low$0.1260 (Dec 21, 2022)
52-week high$0.2097
52-week low$0.1959
Median price$0.1536
Average price$0.1631
Largest weekly change+33.8% (Jun 19, 2024)
Weeks tracked533
Tracking sinceJun 8, 2016

Price History

1W

-1.9%

1M

-1.9%

3M

-5.6%

6M

-2.0%

1Y

-6.5%

3Y

+26.8%

5Y

+22.9%

All

-2.0%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of LITHIUM CARBONATE ER 300 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for LITHIUM CARBONATE ER 300 MG TB, manufactured by Rising Pharma Holdings Inc., is $0.1959 per EA (NDC 64980020505), effective Aug 19, 2026.

How has the price of LITHIUM CARBONATE ER 300 MG TB changed over time?

Over the history we have for it, the NADAC for LITHIUM CARBONATE ER 300 MG TB has held within roughly two percent of its current level. It has been tracked across 533 weekly CMS publications since Jun 8, 2016.

What are the highest and lowest recorded NADAC prices for LITHIUM CARBONATE ER 300 MG TB?

Since Jun 8, 2016, the NADAC for LITHIUM CARBONATE ER 300 MG TB has ranged from a low of $0.1260 (Dec 21, 2022) to a high of $0.2271 (Nov 13, 2024), with a median of $0.1536 per EA.

Are there cheaper alternatives to LITHIUM CARBONATE ER 300 MG TB?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LITHIUM CARBONATE 300 MG TAB, is $0.1934 per EA — about 1% below LITHIUM CARBONATE ER 300 MG TB.

Who manufactures LITHIUM CARBONATE ER 300 MG TB?

LITHIUM CARBONATE ER 300 MG TB (NDC 64980020505) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.